Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 2.11B | 2.07B | 1.86B | 1.62B | 1.27B | 1.19B |
Gross Profit | 847.83M | 416.77M | 356.83M | 335.97M | 235.11M | 195.39M |
EBITDA | 237.96M | 315.48M | 324.26M | 233.76M | 186.00M | 206.71M |
Net Income | -40.72M | -37.81M | -71.47M | -81.30M | -47.79M | 2.16M |
Balance Sheet | ||||||
Total Assets | 4.46B | 4.49B | 4.58B | 4.79B | 4.58B | 3.23B |
Cash, Cash Equivalents and Short-Term Investments | 86.06M | 76.70M | 43.45M | 65.05M | 81.60M | 152.19M |
Total Debt | 0.00 | 1.87B | 3.02B | 3.11B | 2.65B | 1.88B |
Total Liabilities | 2.16B | 2.18B | 3.12B | 3.14B | 2.75B | 2.16B |
Stockholders Equity | 2.26B | 2.26B | 1.27B | 1.40B | 1.58B | 866.11M |
Cash Flow | ||||||
Free Cash Flow | 170.60M | 84.15M | -1.26M | 76.25M | -61.78M | 90.85M |
Operating Cash Flow | 242.66M | 176.09M | 98.53M | 147.77M | 17.91M | 219.16M |
Investing Cash Flow | -36.29M | -8.73M | 9.40M | -118.58M | -138.65M | -147.94M |
Financing Cash Flow | -179.71M | -134.74M | -129.06M | -42.92M | 94.11M | -8.81M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
78 Outperform | $5.98B | 34.00 | 7.02% | 4.29% | 43.27% | 80.97% | |
77 Outperform | $4.43B | 31.51 | 5.15% | 6.45% | 7.81% | 179.16% | |
76 Outperform | $3.31B | 22.47 | 10.56% | 5.08% | 7.44% | 4.23% | |
68 Neutral | $5.99B | ― | -1.93% | 2.70% | 11.30% | ― | |
59 Neutral | $5.59B | ― | -6.83% | 7.79% | -7.26% | 18.45% | |
57 Neutral | $5.79B | 25.71 | -31.22% | 5.58% | 10.88% | -29.73% | |
52 Neutral | $2.63B | ― | -28.86% | 7.31% | 19.56% | -12.73% |
On June 25, 2025, American Healthcare REIT, Inc. held its Annual Meeting of Stockholders where four key proposals were voted upon. The stockholders elected nine directors for a one-year term, ratified Deloitte & Touche as the independent accounting firm for 2025, approved executive compensation for 2024 on an advisory basis, and approved the 2025 Manager Equity Plan. These decisions reflect the company’s ongoing governance and strategic planning efforts, potentially impacting its operational and financial management in the coming year.
The most recent analyst rating on (AHR) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on American Healthcare REIT, Inc. stock, see the AHR Stock Forecast page.
On June 20, 2025, American Healthcare REIT, Inc. announced a quarterly distribution of $0.25 per share for the second quarter of 2025, payable on or about July 18, 2025, to shareholders of record as of June 30, 2025. This distribution reflects an annualized rate of $1.00 per share and underscores the company’s commitment to providing returns to its investors, potentially enhancing its attractiveness in the real estate investment sector.
The most recent analyst rating on (AHR) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on American Healthcare REIT, Inc. stock, see the AHR Stock Forecast page.
On May 8, 2025, American Healthcare REIT, Inc. announced its first quarter 2025 results, reporting a GAAP net loss attributable to controlling interest of $6.8 million and a GAAP net loss per diluted share of $0.04. Despite this, the company achieved a 15.1% growth in Same-Store Net Operating Income (NOI) compared to the previous year, driven by strong performance in its senior housing operating properties and integrated senior health campuses. The company also increased its full-year 2025 guidance, reflecting improved expectations for NOI growth and earnings, supported by successful capital markets activity and strategic asset transactions. The company remains focused on leveraging demand for long-term care and pursuing new growth opportunities.